Time for global efforts with clinical trials for advanced cervical cancer patients

Clinical outcome of FIGO 2018 stage IB3/IIA2 cervical cancer treated by neoadjuvant chemotherapy followed by radical surgery due to lack of radiotherapy equipment: A retrospective comparison with concurrent chemoradiotherapy

“…Bulky tumor volumes characterized LACC. Several studies reported that the 5-year OS of IB2-IIA patients with tumors diameter greater than 4 cm is 30%-60% with the surgical intervention [25,28,29]. Our evaluation of NACT-RS was consistent with tumor volume reduction.…”

Downregulation of ERp57 expression is associated with poor prognosis in early-stage cervical cancer

“…According to official statistics, more than 50% of all cases and deaths from the disease worldwide were reported in the Asia Oceania region, with the highest incidence and mortality rates in South Central and Southeast Asia (Garland et al, 2012). The high mortality is ascribed to disease recurrence after cervix resection and lack of effective treatment for advanced stage disease (Chun, 2009). Although many clinicopathological factors have been described as prognostic tools, a limited number of these parameters have been incorporated and used in the clinic.…”

Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2–IIB cervical cancer

“…Several studies have reported that the 5-year OS of IB2-IIA patients with tumors with a diameter of more than 4 cm is 30%-60% with surgical intervention, although the rate of lymph node positivity is 35%-80%, resulting in a 5-year survival rate of 30%-40% [13,[19][20][21]. The National Cancer Institute describes cisplatin-based concurrent chemoradiation as the standard treatment for LACC on the basis of 5 randomized studies containing nearly 2000 patients.…”